|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OVOL1 |
Gene summary for OVOL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OVOL1 | Gene ID | 5017 |
| Gene name | ovo like transcriptional repressor 1 | |
| Gene Alias | HOVO1 | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O14753 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5017 | OVOL1 | P39T-E | Human | Esophagus | ESCC | 5.51e-17 | 6.90e-01 | 0.0894 |
| 5017 | OVOL1 | P42T-E | Human | Esophagus | ESCC | 1.75e-11 | 1.39e+00 | 0.1175 |
| 5017 | OVOL1 | P47T-E | Human | Esophagus | ESCC | 5.98e-17 | 6.80e-01 | 0.1067 |
| 5017 | OVOL1 | P48T-E | Human | Esophagus | ESCC | 1.73e-05 | 4.63e-01 | 0.0959 |
| 5017 | OVOL1 | P49T-E | Human | Esophagus | ESCC | 7.03e-04 | 1.35e+00 | 0.1768 |
| 5017 | OVOL1 | P54T-E | Human | Esophagus | ESCC | 2.41e-31 | 1.22e+00 | 0.0975 |
| 5017 | OVOL1 | P57T-E | Human | Esophagus | ESCC | 9.14e-05 | 3.76e-01 | 0.0926 |
| 5017 | OVOL1 | P62T-E | Human | Esophagus | ESCC | 1.78e-45 | 2.15e+00 | 0.1302 |
| 5017 | OVOL1 | P65T-E | Human | Esophagus | ESCC | 2.15e-02 | 3.34e-01 | 0.0978 |
| 5017 | OVOL1 | P74T-E | Human | Esophagus | ESCC | 7.02e-15 | 1.50e+00 | 0.1479 |
| 5017 | OVOL1 | P75T-E | Human | Esophagus | ESCC | 1.59e-51 | 1.92e+00 | 0.1125 |
| 5017 | OVOL1 | P79T-E | Human | Esophagus | ESCC | 8.99e-06 | 2.84e-01 | 0.1154 |
| 5017 | OVOL1 | P80T-E | Human | Esophagus | ESCC | 1.08e-61 | 2.76e+00 | 0.155 |
| 5017 | OVOL1 | P83T-E | Human | Esophagus | ESCC | 1.54e-03 | 3.92e-01 | 0.1738 |
| 5017 | OVOL1 | P107T-E | Human | Esophagus | ESCC | 5.67e-04 | 6.42e-01 | 0.171 |
| 5017 | OVOL1 | P126T-E | Human | Esophagus | ESCC | 2.77e-03 | 1.22e+00 | 0.1125 |
| 5017 | OVOL1 | P127T-E | Human | Esophagus | ESCC | 6.20e-32 | 1.17e+00 | 0.0826 |
| 5017 | OVOL1 | P128T-E | Human | Esophagus | ESCC | 1.64e-08 | 7.87e-01 | 0.1241 |
| 5017 | OVOL1 | P130T-E | Human | Esophagus | ESCC | 2.39e-33 | 1.83e+00 | 0.1676 |
| 5017 | OVOL1 | C04 | Human | Oral cavity | OSCC | 4.51e-14 | 9.67e-01 | 0.2633 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
| GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
| GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
| GO:19019883 | Esophagus | ESCC | negative regulation of cell cycle phase transition | 151/8552 | 249/18723 | 1.28e-06 | 1.57e-05 | 151 |
| GO:004593013 | Esophagus | ESCC | negative regulation of mitotic cell cycle | 143/8552 | 235/18723 | 1.84e-06 | 2.15e-05 | 143 |
| GO:000991310 | Esophagus | ESCC | epidermal cell differentiation | 122/8552 | 202/18723 | 1.69e-05 | 1.51e-04 | 122 |
| GO:00016559 | Esophagus | ESCC | urogenital system development | 177/8552 | 338/18723 | 7.51e-03 | 2.69e-02 | 177 |
| GO:00073469 | Oral cavity | OSCC | regulation of mitotic cell cycle | 266/7305 | 457/18723 | 3.87e-17 | 3.41e-15 | 266 |
| GO:19019875 | Oral cavity | OSCC | regulation of cell cycle phase transition | 209/7305 | 390/18723 | 2.79e-09 | 6.42e-08 | 209 |
| GO:00457879 | Oral cavity | OSCC | positive regulation of cell cycle | 173/7305 | 313/18723 | 3.28e-09 | 7.44e-08 | 173 |
| GO:00457864 | Oral cavity | OSCC | negative regulation of cell cycle | 206/7305 | 385/18723 | 4.28e-09 | 9.55e-08 | 206 |
| GO:00459304 | Oral cavity | OSCC | negative regulation of mitotic cell cycle | 132/7305 | 235/18723 | 6.51e-08 | 1.16e-06 | 132 |
| GO:00435887 | Oral cavity | OSCC | skin development | 143/7305 | 263/18723 | 2.77e-07 | 4.27e-06 | 143 |
| GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
| GO:19019882 | Oral cavity | OSCC | negative regulation of cell cycle phase transition | 136/7305 | 249/18723 | 3.81e-07 | 5.70e-06 | 136 |
| GO:00109483 | Oral cavity | OSCC | negative regulation of cell cycle process | 155/7305 | 294/18723 | 1.11e-06 | 1.48e-05 | 155 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| OVOL1 | INCAF | Prostate | ADJ | OAS1,EPS8L1,ARL17B, etc. | 3.16e-02 |  |
| OVOL1 | INFIB | Prostate | Healthy | OAS1,EPS8L1,ARL17B, etc. | 1.89e-01 |  |
| OVOL1 | BAS | Skin | Healthy | ZNF750,CLDN4,RHOV, etc. | 2.11e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OVOL1 | SNV | Missense_Mutation | novel | c.625C>T | p.Arg209Trp | p.R209W | O14753 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| OVOL1 | SNV | Missense_Mutation | novel | c.256N>C | p.Asp86His | p.D86H | O14753 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| OVOL1 | SNV | Missense_Mutation | novel | c.727C>T | p.Arg243Cys | p.R243C | O14753 | protein_coding | deleterious(0) | possibly_damaging(0.818) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| OVOL1 | SNV | Missense_Mutation | rs774919756 | c.593G>A | p.Gly198Asp | p.G198D | O14753 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OVOL1 | SNV | Missense_Mutation | rs199678307 | c.391C>T | p.Arg131Cys | p.R131C | O14753 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| OVOL1 | SNV | Missense_Mutation | c.119C>T | p.Pro40Leu | p.P40L | O14753 | protein_coding | tolerated(0.16) | probably_damaging(0.994) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| OVOL1 | SNV | Missense_Mutation | novel | c.223N>A | p.Gly75Arg | p.G75R | O14753 | protein_coding | tolerated(0.09) | benign(0.068) | TCGA-AF-2691-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OVOL1 | SNV | Missense_Mutation | novel | c.625N>T | p.Arg209Trp | p.R209W | O14753 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OVOL1 | SNV | Missense_Mutation | rs577150616 | c.427N>A | p.Val143Ile | p.V143I | O14753 | protein_coding | deleterious(0.04) | benign(0.061) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OVOL1 | SNV | Missense_Mutation | novel | c.223N>A | p.Gly75Arg | p.G75R | O14753 | protein_coding | tolerated(0.09) | benign(0.068) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |